Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A2 | P11168 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | KCNK3 | O14649 | 9/20 | 0.49 |
| ▸ | KCNK9 | Q9NPC2 | 9/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6664782 | 0.84 | SLC2A2 (0.66) | SLC2A2KDM4EGAASLC2A1SMN1; SMN2 | |
| SCHEMBL28620843 | 0.81 | SLC2A1 (0.82) | KDM4EGAASLC2A1SMN1; SMN2ALDH1A1 | |
| SCHEMBL13234 | 0.77 | GABRA2 (0.63) | SLC2A2KDM4ESMN1; SMN2RAB9AKCNK3 | |
| SCHEMBL17719063 | 0.76 | SLC2A2 (1.00) | SLC2A2SLC2A1 | |
| SCHEMBL17718815 | 0.76 | GAA (0.64) | GAAKCNK3KCNK9 | |
| SCHEMBL6686729 | 0.75 | NTRK1 (0.58) | KDM4EGAASLC2A1SMN1; SMN2ALDH1A1 | |
| SCHEMBL22364216 | 0.75 | KCNK3 (0.73) | GAASLC2A1KCNK3KCNK9 | |
| SCHEMBL22364214 | 0.73 | KCNK3 (0.78) | SLC2A1KCNK3KCNK9 | |
| SCHEMBL30416749 | 0.73 | GABRA2 (0.63) | SLC2A2KDM4EGAASLC2A1SMN1; SMN2 | |
| SCHEMBL13341887 | 0.72 | SMN1; SMN2 (0.56) | KDM4ESLC2A1SMN1; SMN2ALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1311508-B1 | NOVEL BETA-AMYLOID INHIBITORS, METHOD FOR PRODUCING THE SAME AND THE USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA (DE) | 2004-11-17 | — | — | EP | disclosed |
| US-20020042420-A1 | Beta-amyloid inhibitors, processes for preparing them, and their use in pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042420-A1 | Beta-amyloid inhibitors, processes for preparing them, and their use in pharmaceutical compositions | HTT, APP, BACE1 | SLC2A2 931/4885KDM4E 4232/4885GAA 255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.